Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00194714 · ClinicalTrials.gov registry record · Phase 1
Vaccine Therapy in Treating Patients With Stage IV HLA-A2 and HER2 Positive Breast or Ovarian Cancer Receiving Trastuzumab
A Phase 1 study, sponsored by University of Washington.
- Completed
- Registry status
- Phase 1
- Development phase
- 22
- Enrollment target
NCT00194714 is a Phase 1 study that has completed, run by University of Washington. The registered enrollment target is 22 participants.
The verdict
NCT00194714, a Phase 1 study, has completed, sponsored by University of Washington.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 22 participants
- Enrollment target
Study Summary
This phase I/II trial studies the side effects of vaccine therapy and to see how well it works in treating patients with stage IV major histocompatibility complex, class I, A2 antigen (HLA-A2) and human epidermal growth factor receptor 2 (HER2) positive breast or ovarian cancer who are receiving trastuzumab. Giving booster vaccines made from HER2 peptides may help increase HER2 specific immunity and immune memory cells.
Interventions
- OTHER Laboratory Biomarker Analysis
- BIOLOGICAL HER-2/neu Peptide Vaccine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 22 participants |
| Start Date | 2016-05 |
| Est. Completion | 2023-05-22 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00194714
The ClinicalTrials.gov registry entry for NCT00194714 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 22 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Washington, which has 1,048 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Laboratory Biomarker Analysis is the first listed.
NCT00194714 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00194714 about?
NCT00194714 is a clinical study titled "Vaccine Therapy in Treating Patients With Stage IV HLA-A2 and HER2 Positive Breast or Ovarian Cancer Receiving Trastuzumab". This phase I/II trial studies the side effects of vaccine therapy and to see how well it works in treating patients with stage IV major histocompatibility complex, class I, A2 antigen (HLA-A2) and human epidermal growth factor receptor 2 (HER2) positive breast or ovarian cancer who are receiving tra...
What is the current status of trial NCT00194714?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 22 participants. The study started on 2016-05. Estimated completion is 2023-05-22.
What interventions are being tested in trial NCT00194714?
The interventions under investigation include: Laboratory Biomarker Analysis (OTHER), HER-2/neu Peptide Vaccine (BIOLOGICAL).
Who is sponsoring clinical trial NCT00194714?
This trial is sponsored by University of Washington, which has 1,048 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.